Ibrutinib may be a potential drug to treat B‐ALL because it can inhibit the phosphorylation of CXCR4 induced by SDF‐1 and the expression and activation of ERK and BCL‐xL.115. The gene discussed is CXCR4; the disease is acute lymphoblastic leukemia.